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doi:10.1016/j.pedneo.2012.04.005Background: Vagus nerve stimulation (VNS), an alternative method to manage patients with
medically intractable epilepsy, has shown favorable results in reducing seizure relapse and
improvements in quality of life. In 1997, the U.S. Food and Drug Administration approved
the use of this device as an adjunctive therapy for intractable seizure in adults and adolescents
older than 12 years of age.
Methods: We present a preliminary study of pediatric patients, who suffered from medically
intractable seizure and underwent VNS implantation after observation of the baseline seizure
frequency. Classification of epileptic syndrome, seizure patterns, age of onset, seizure
frequency reduction and adverse effects were recorded.
Results: Patients who underwent VNS implantation included four adolescents and four chil-
dren. The follow-up duration ranged from 9e33 months. All the patients were responders after
the beginning of the stimulation. Five of the eight patients responded to VNS with a seizure
frequency reduction rate > 50%, and four of the eight patients experienced a  90% seizure
reduction. No significant adverse effects were noted in all patients during the observation
period.of Pediatrics, Chung Shan Medical University Hospital, Number 110, Section 1, Jianguo North Road,
hinet.net (J.-D. Tsai).
an Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
Vagus nerve stimulation in pediatric patients 185Conclusion: The effective management of medically intractable seizure remains challenging to
most clinical physicians. In addition to ketogenic diet and epilepsy surgery, VNS provides an
alternative way to manage this issue. Our results suggest that VNS is well tolerated in pediatric
patients, and is a favorable and safe method of treating intractable seizure in common clinical
practice.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Despite the number of different antiepileptic drugs (AED)
currently available in the management of epilepsy with
optimal drug administration, about one fourth of patients
cannot achieve seizure-free status. Of course, some of
these patients can benefit from epileptic surgery, which is
generally considered as a safe and effective treatment for
medically refractory epilepsies.1 However, physiologic and
anatomic limitations have been linked to surgical failure.2
For those who are not candidates for epileptic focus
resection or do not benefit from surgery, vagus nerve
stimulation (VNS) provides an alternative and effective
choice for seizure control.3,4 In 1997, the U.S. Food and
Drug Administration approved VNS to be indicated for use as
an adjunctive therapy in reducing the frequency of medi-
cally intractable seizures in adults and adolescents older
than 12 years of age.5 The efficacy of VNS in the treatment
of variable types of medically refractory epilepsy has been
demonstrated.6 Several studies have shown the efficacy of
VNS in seizure reduction. The mean percentage of seizure
reduction for adult patients with a >50% reduction rate has
been estimated at approximately 50%e60% of all patients.3,4
The responder rate has been reported as being in concor-
dance with a decrease in overall seizure frequency.
Although it was approved for use with adults and adoles-
cents, VNS is also effective and safe in cases of childhood
epilepsy.7 In addition to its indication for focal epilepsy,
VNS is suggested to be effective in epileptic syndrome.8
In this preliminary study, we examine the efficacy and
outcome of using this method in pediatric patients,
including adolescents and children younger than 12 years
old with medically refractory epilepsy.
2. Methods
This study was retrospective, multi-centered and open-
labeled. The patients with medically intractable seizures
were defined as refractory epilepsy on two or more AEDs.
All patients had been previously followed up for at least 2
years, and had undergone detailed clinical-history taking,
several types of medication, brain magnetic resonance
imaging and electroencephalogram. After observation of
the baseline seizure frequency and seizure types, the VNS
devices were implanted. The follow-up periods for all
participants were at least 12 months.
The devices used for VNS were purchased from Cyber-
onics (Houston, TX, USA). The VNS generators were
implanted in subcutaneous pockets on the pectoralis fasciathrough a 1-2 cm incision in the left-side anterior axillary
fold. Each stimulation lasted for 30 seconds, at 30 Hz
frequency and 500 usec pulse width, with 5 minutes
between stimulations and 0.25 mA output current initially
for each patient. Adjusted output current was set at
maximum of 1.5 mA in accordance with the manufacturer’s
guidelines.
Eight pediatric patients (seven males and one female)
with medically refractory epilepsies, who had undergone
VNS device implantation between Feb 2008 and Mar 2010,
were enrolled in the study. Patients were aged from 4 years
to 17 years of age, and durations of seizure disorder ranged
from 2e14 years. Specific epileptic syndromes were diag-
nosed by clinical physicians if possible. Etiologies included
two cryptogenic etiologies, three encephalitis, and three
epileptic syndromes (one severe myoclonic epilepsy of
infancy, one West syndrome, and one Lennox-Gastaut
syndrome). None of the patients had an underlying meta-
bolic disorder. Before implantation of VNS, all patients had
received three to four antiepileptic drugs at therapeutic
levels. None of the patients had ever been put on a keto-
genic diet or received epilepsy surgery before implantation
(Table 1). Based on the effectiveness of VNS, patients were
classified into seizure reduction levels, including > 90%
seizure reduction, > 50% seizure reduction, and < 50%
seizure reduction. Patients with seizure reduction of more
than 50% were considered as a VNS responder.
All patients had a psychologic evaluation before VNS
initiation, and all of these children were cognitively
impaired. They were classified as severe mental retarda-
tion, moderate mental retardation, or mild mental retar-
dation as assessed with the Bayley Scales of Infant
Development or the Wechsler’s Pre-school and Primary
Scale of Intelligence.3. Results
Prior to VNS, patients had a seizure frequency ranging from
one to two episodes per month to 10 episodes per week.
After implantation of VNS, four of the eight patients had
a > 90% seizure frequency reduction, one (1/8) had a 50% to
90% seizure reduction, and three (3/8) had a < 50% seizure
reduction; no child became seizure-free. In cryptogenic
epilepsies and epileptic syndromes, three patients showed
a > 90% seizure frequency reduction and two had a < 50%
seizure frequency reduction. In cases of encephalitis-
related seizure, three patients showed a mild response,
including one patient with a > 90% seizure frequency
reduction, one with a 50%e90% seizure frequency reduction
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186 C.-Y. Chen et aland one with a < 50% seizure reduction. By age, patients
included four adolescents (12e18 years old) and four chil-
dren (younger than 12 years of age). Three of the adoles-
cents had a < 50% seizure frequency reduction, and only
one had a > 90% seizure frequency reduction. In patients
younger than 12 years, three showed a > 90% reduction in
seizure frequency and one of the patients showed a 50%e
90% seizure frequency reduction (Table 2).
Half of the patients remained on the same medications
during follow-up, and only two patients were able to have
their therapeutic regimens decreased. For the remaining two
patients, one AED was tapered but later replaced by a new
medication. With regard to adverse effects, only two
patients complained of hoarseness, and there were no other
significant adverse effects for the remainder of the patients.
All patients had a neuropsychological evaluation before
VNS initiation, and all of these patients were affected with
regards to cognition status. They were classified as severe
mental retardation in two patients, moderate mental
retardation in one, and mild mental retardation in one as
assessed using the Wechsler’s Pre-school and Primary Scale
of Intelligence. After implantation of VNS, all but two
patients showed improvement with respect to emotion
control, verbal ability and school performance.4. Discussion
In longitudinal follow-up studies, more than 60% of adult
and adolescent patients were responders to VNS treatment
at the 5-year follow-up, and 5%e10% were seizure-free.3,4
VNS therapy is also effective and safe in pediatric
patients with refractory seizures. It was reported that VNS
achieved for children with refractory epilepsy reduction in
seizure frequency, severity and improvement in their
quality of life.9 Seizure severity and frequency, as well as
quality of life, improved with VNS therapy without signifi-
cant adverse events in patients who were younger than 18
years of age.10 The overall seizure reduction rate varies
between 45% and 70% by follow-up ranging from 6 to 12
months.7,11,12 In comparison, we report half of all patients
had a > 90% seizure reduction, one had a > 50% seizure
reduction and three had a < 50% seizure reduction, and no
child became seizure-free.
Despite VNS being approved for focal epilepsies, it has
been suggested that VNS is useful in cases involving most
epileptic syndromes.8 The efficacy of VNS in treating focal
epilepsies and various types of generalized epilepsies,
including idiopathic generalized epilepsy and Lennox-
Gastaut syndrome, have been adequately demonstrated.3
Similar to previous studies, we observed the efficacy of
VNS therapy was effective in cases of cryptogenic epilep-
sies or epileptic syndromes and those with organic
lesions.11 We propose seizure reduction in our patients was
related to the etiologies despite the limited number of
patients in our study.
In addition to reducing seizure frequency, VNS was
associated with improvements in quality of life, including
verbal ability and school performance. This effect may not
relate to the antiepileptic effect.13 The nonpharmacologic
aspect of VNS therapy makes it particularly attractive for
use, due to its minimal side effects and cognition
Table 2 Seizure reduction, adverse effects, and quality of life improvement after VNS implantation.
Pt No Seizure
frequency
Follow-up
duration (m)
Medication Adverse effect
Baseline Reduction (%) Before VNS After VNS
1 1e2/mo < 50% 33 CBZ-XR,CZP TPM CBZ-XR,CZP TPM No
2 6e8/mo > 90% 29 VPA, LMT, LEV CZP, LMT, LEV No
3 1e3/mo > 90% 24 CZP, TPM, LMT CZP, TPM, LMT Hoarseness
4 5e10/mo < 50% 24 CBZ-XR, TPM,CLB CBZ-XR, TPM,CLB Hoarseness
5 1e2/wk < 50% 20 VPA,CBZ-XR, TPM, CBZ-XR, TPM, No
6 10/mo > 90% 13 VGB,VPA, CZP, TPM VGB,VPA, CZP, TPM No
7 3e4/wk > 50% 9 VPA, LTG, PHT VPA, CZP, PHT No
8 20e30/d > 90% 9 VPA, CZP, TPM VPA, CZP No
CBZ-XR Z oxcarbazepine; CLB Z clobazam; CZP Z clonazepam; LEV Z levetiracetam; LMT Z lamotrigine; PHT Z phenobarbital;
TPM Z Topamax; VGB Z vigabatrin; VNS Z vagus nerve stimulation; VPA Z valproate.
Vagus nerve stimulation in pediatric patients 187impairment with AEDs in pediatric patients.10 A review of
pediatric patients from VNS outcome showed alertness was
improved in more than 70% of children studied.14
Not only patients with refractory epilepsy can benefit
from VNS, but also patients with austic spectrum have been
shown to demonstrate improved alertness.15 Most of the
adverse effects were mild and transient with improvement
of seizure frequency, and could be controlled by adjusting
the current output.7 As previous study, common adverse
effects included cough, hoarseness, mild dysphasia, throat
pain, chest discomfort and dyspnea.16 A large series study
reported adverse effects occurred in 68% of pediatric
patients, but most were mild or transient.11 A 5-year
longitudinal follow-up study suggested only intolerable
symptoms, implantation complication or device failure
would be considered as adverse effects, which resulted in
only 13.3% of patients experiencing subsequent adverse
effect.3 By comparison, only hoarseness occurred in two (2/
8) of our patients, and no device failure or surgical
complication occurred in the remaining patients. We
supposed most of our pediatric patients were cognition-
impaired and consequently unable to actively describe
their discomforts.
In conclusion, our study indicates that VNS is effective
and safe in pediatric refractory epilepsy, especially with
regard to epileptic syndrome and in children. It also
possesses several advantages including minimal adverse
effects and reducing AED burden. Based on these observa-
tions, we suggest that VNS should be considered as an
alternative therapy when a patient is determined to be
medically refractory, especially for children younger than
12 years of age.
Acknowledgments
This study is supported by Taiwan Child Neurology Society.
References
1. Sharon SD. The epidemiology and treatment of chronic and
refractory epilepsy. Epilepsia 1996;37(Suppl. 2):S1e3.2. Noachtar S. Borggraefe I.Epilepsy surgery: a critical review.
Epilepsy Behav 2009;15:66e72.
3. Kuba R, Bra´zdil M, Kalina M, et al. Vagus nerve stimulation:
longitudinal follow-up of patients treated for 5 years. Seizure
2009;18:269e74.
4. Ghaemi K, Elsharkawy AE, Schulz R, et al. Vagus nerve stimu-
lation: outcome and predictors of seizure freedom in long-term
follow-up. Seizure 2010;19:264e8.
5. Schachter SC. Vagus nerve stimulation therapy summary: five
years after FDA approval. Neurology 2002;59(6 Suppl 4):
S15e20.
6. Mu¨ller K, Fabo´ D, Entz L, et al. Outcome of vagus nerve stim-
ulation for epilepsy in Budapest. Epilepsia 2010;51(Suppl 3):
98e101.
7. You SJ, Kang HC, Kim HD, et al. Vagus nerve stimulation in
intractable childhood epilepsy: a Korean multicenter experi-
ence. J Korean Med Sci 2007;22:442e5.
8. Labar D, Murphy J, Tecoma E. Vagus nerve stimulation for
medication-resistant generalized epilepsy. E04 VNS Study
Group. Neurology 1999;52:1510e2.
9. Lundgren J, Amark P, Blennow G, Stromblad LG, Wallstedt L.
Vagus nerve stimulation in 16 children with refractory epilepsy.
Epilepsia 1998;39:809e13.
10. Wheless JW, Maggio V. Vagus nerve stimulation therapy in
patients younger than 18 years. Neurology 2002;59(6 Suppl 4):
S21e5.
11. Rossignol E, Lortie A, Thomas T, et al. Vagus nerve stimulation
in pediatric epileptic syndromes. Seizure 2009;18:34e7.
12. Murphy JV, Torkelson R, Dowler I, Simon S, Hudson S. Vagal
nerve stimulation in refractory epilepsy: the first 100 patients
receiving vagal nerve stimulation at a pediatric epilepsy
center. Arch Pediatr Adolesc Med 2003;157:560e4.
13. Hallbo¨o¨k T, Lundgren J, Stjernqvist K, Blennow G,
Stro¨mblad LG, Rose´n I. Vagus nerve stimulation in 15 children
with therapy resistant epilepsy: its impact on cognition,
quality of life, behaviour and mood. Seizure 2005;14:504e13.
14. Parker AP, Polkey CE, Binnie CD, Madigan C, Ferrie CD,
Robinson RO. Vagal nerve stimulation in epileptic encepha-
lopathies. Pediatrics 1999;103:778e82.
15. Park YD. The effects of vagus nerve stimulation therapy on
patients with intractable seizures and either Landau-
Kleffner syndrome or autism. Epilepsy Behav 2003;4:
286e90.
16. Smyth MD, Tubbs RS, Bebin EM, Grabb PA, Blount JP. Compli-
cations of chronic vagus nerve stimulation for epilepsy in
children. J Neurosurg 2003;99:500e3.
